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Effect of antenatal steroid treatment on fetal and maternal endocrine      
                                             parameters 
 
 
1. Summary 
 
 
Strong evidence exists for the role of antenatal steroids in Respiratory Distress 
Syndrome (RDS) prevention, the protocol for the steroid administration is evidence 
based. Glucocorticoids are essential for pulmonary development in fetuses and preterm 
infants, but the effect is not limited to lung development. 
The accelerated maturation of organs might be taken that „hormonal imprinting” effect 
of glucocorticoids. 
The first part of  dissertation  deals with glucocorticoid receptors of human fetal lung.  
From the scientific point of view these results are not „novum”. But the second part of 
dissertation deals with a new peptid, ghrelin  and  possible correlation with endocrine 
and anthropometric parameters during pregnancy.  
Ghrelin plays an important role in the regulation of appetite and food intake and controls 
of energy balance. This peptide is produced predominantly by the stomach, whereas 
lower amounts are derived from the hypothalamus, kidney, heart, pancreatic cells, and 
the placenta in humans. The presence of significant ghrelin concentrations in human 
cord blood has been shown, but information about the ghrelin secretion during the fetal 
life is scarce. It is known that the hypercortisolism in humans decreases ghrelin levels in 
plasma and  that serum cortisol exhibits a negative correlation with ghrelin. The 
physiological mechanisms behind this relationship are not known, but the 
glucocorticoids that are used in antenatal therapeutic settings may have an effect on 
ghrelin secretion.  
The point of the present study was to compare acylated and total ghrelin concentration in 
premature infants and their mothers and to investigate the possible relationship between 
ghrelin and anthropometric and hormonal parameters, such as leptin, insulin, growth 
hormone and cortisol. 
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2. Introduction 
 
 
 
In the 1972  Liggins and Howie were the first to propose  the antenatal corticosteroids 
given to mothers at risk of preterm delivery. Glucocorticoids appear to have, besides the 
stimulation of surfactant, additional effects on pulmonary maturation. Since then, many 
other randomized controll and meta-analysis have reported the clinical benefits of 
antenatal corticosteroids. In 1994  the National Institute of Health  declared a cosensus 
statement: all pregnant women between 24 and 34 weeks gestation, who are at risk of 
preterm delivery, should be candidates for antenatal treatment with corticosteoids. In 
Hungary Szabó and coworkers were the first to introduce the antenatal corticosteroid 
treatment in the clinical practice. 
Antenatal corticosteroids also protect the newborn from intraventricular haemorrhagie 
and necrotizing enterocolitis especially in extremely low birthweight infants. 
There is no evidence that the repeated courses of prenatal steroids have higher efficiency 
in the prevention of RDS, but several clinical studies observed, that increasing numbers 
of antenatal corticosteroid courses were associated with reduction in birthweight. 
The exact mechanism of glucocorticoid-induced lung maturation is still unknown. In 
most species, including humans, a late gestational rise in fetal cortisol production is 
found combined with a high expression of glucocorticoid receptors in pulmonary tissues. 
Hypophysectomy in several species  causes abnormal lung development, suggesting that 
low levels of cortisol are linked with an inhibition of pulmonary maturation.  
We measured glucocorticoid receptor concentration in human lung cytosol from fetuses 
of gestational age 14-28 wk. The concentration of cytoplasmic receptor arranged 
according to the gestational age are presented in Fig.1. Characterization of the in vitro 
binding of glucocorticoid by lung cytosol showed a high affinity, saturable  receptors for 
natural and synthetic glucocorticoids. In evaluating ontogeny of receptor in human lung 
tissue showed  a decrease in the receptor number at the end of canalicular phase.  This 
time is the end of cellular proliferation of the lung and there is a marked decrease in 
interstitial tissue.  
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 Figure 1. Cortisol cytoplasmic reception in                        Figure 2. Mean cortisol receptor numbers in 
  human fetal lung  n=47,  Spearman k=0.015                      anencephal ( ) n=9 and normal ( ) n=18                                  
                                                                                               fetal lung 
 
 
The cortisol binding examination of anencephal human fetal lung revealed the 
importance of hypothalamo-hypophyseal-adrenal axis in the normal development of 
cotisol receptors. (Fig.2.)  
 
In 2002  a   new hormone, ghrelin was idenfied in the neuroendocrine cells of human 
fetal lung. The extent of ghrelin expression differed according to the gestational age, the 
cut off point to separate the expression was the 18-20 week of gestation. It was declared, 
that the human fetal lung is an important source of ghrelin. It can be speculated that 
ghrelin may play a role in lung maturation and elongation. 
The ghrelin was discovered in 1999, through a process of reverse pharmacology has 
been shown to be a natural ligand of the growth hormone secretagouge (GHS) receptor. 
 
Structure of Ghrelin 
                                            
 
It is a peptide hormone of 28 amino acids possessing an unusual octanoyl goup on the 
serin in position 3, which is crucial for its GHS activity. This peptide is produced 
predominantly by the stomach, whereas lower amounts are derived from the 
hypothalamus,  pancreatic cells, kidney and placenta in humans. During the fetal life 
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after the stomach, the main source of ghrelin the neuroendocrine cells of lung and the 
pancreas B cells. Although in the beginning it was widely  accepted that unacylated 
ghrelin was devoid of any biological activity , recently is considered  as a peptide with 
wide range actions in different tissues. The best investigated ghrelin receptor, GHS-R1, 
has two variants, GHS-R1a and GHS-R1b, which result from alternative splicing of the 
same gene. GHS-R1a is expressed highly in the hypothalamus and pituitary and  the 
octanoylation  is essential for binding to it. 
The octanoylated ghrelin has the GH-releasing effect and control of apetite, food intake 
and energy balance. The GHS-R1a and GHS-R1b and ghrelin are present in human 
endocrine pancreas suggesting  that ghrelin may play a role in the glucose metabolism. 
Depending on the experimental conditions, ghrelin is reported to either inhibit or 
stimulate insulin secretion in humans. Ghrelin has both orexigenic and adipogenic 
effects and there is a negative correlation between total ghrelin and body mass index, 
insulin and leptin in lean and obese humans.  
Ghrelin was detected in human placental tissue in 2001, and the receptor type GHS-R1b 
binding unacylated  ghrelin was  observed in placental and endometrial tissue.  The 
presence of significant ghrelin concentrations in human cord blood has been shown but 
information about the ghrelin secretion during fetal life is scarce.  
The source  of ghrelin on cord plasma is unknown: it may have originated from the 
maternal compartment, may be secreted by the placenta or may come directly from the 
fetal tissues. Concentration of total ghrelin in cord blood of small-for-gestational age 
infants were significantly greater than in appropriate-for-gestational age at different 
times of gestation. The „catch-up growth”  of infants is known, but the physiological 
mechanism behind it is unknown.  
The possible role of ghrelin during pregnancy was examined  in rat fetal development. 
The administration of acyl-ghrelin to female  pregnant rats indicated that maternal acyl-
ghrelin can easily transit to the fetal circulation. The prolonged maternal treatment with 
acyl-ghrelin during pregnancy significantly increased the average neonatal body weight 
at birth in comparisone to that of neonates delivered by saline-treated group. No 
signficant changes were observed after treatment with des-acyl ghrelin.  When pregnant 
females treated with acyl-ghrelin consumed the same amount of food as saline-treated 
pregnant females, neonatal body weight was significantly greater in the ghrelin-treated 
group. 
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The multiple activities of ghrelin also include stimulatory effects on the corticotropic 
system, as systemic administration of ghrelin induces an increase in ACTH and cortisol 
levels in healthy subjets and shows a remarkable hyper-responsiveness of ACTH and 
cortisol secretion in patients with active Cushing’s  syndrome.  It is known that the 
hypercortisolism in humans decreases total ghrelin levels in plasma and that serum 
cortisol exhibits a negative correlation with total ghrelin. The physiological mechanisms 
behind this relationship are not known, but the glucocorticoids that are used in antenatal 
therapeutic settings may have an effect on ghrelin secretion.  
 
 
 
3. Objectives 
 
The point of the present study was to compare acylated and total ghrelin concentration in 
premature infants and their mothers and to investigate the possible relationship between 
ghrelin and anthropometric and hormonal parameters, such as leptin, insulin, GH and 
cortisol.  
 
 
4. Patients and methods 
                  
    4.1    Patients 
 
The 26 preterm infants (gestational age 25-35 weeks) and their  mothers were involved 
in the study. Three women with twin pregnancies were included into the protocol 
together with their newborns. Mothers with pre-eclampsia, hypertension, or diabetes 
were excluded. Cesarean section was used for eight mothers. 
The infants who were appropriate for gestational age participated in this study. It was 
defined as birth weight from -1.5 to + 1.5 S.D. of the mean birth weight in each 
gestational age according to current Hungarian standard. All mothers received 
betamethasone  for the prevention of respiratory distress syndrome.  The time interval 
between the steroid injection and the birth varied from 10h to 7 days. 
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4.2 Laboratory methods 
 
Immediately after delivery, a venous cord blood sample was collected from newborns 
and also from mothers. The tubes containing EDTA with aprotinin were kept at 4°C 
before centrifugation and were centrifuged within 1h. The plasma samples were stored at 
-70°C. Acylated and total ghrelin, and leptin were measured with commercially 
available RIA kit (Linco Research Inc.USA). Cortisol, insulin and GH were assayed 
with RIA and IRMA kit (Isotope Ins.Hungary). Glucose was measured by glucose 
hexokinase method ( Merck ). 
 
 
4.3 Statistical methods 
 
Comparative analyses between maternal and fetal data were calculated by Mann-
Whitney test. The correlations were analyzed by Spearman’s correlation  test.  The 
Multiple Regression Model was created using stepwise method to verify the influence of 
different variables on fetal and maternal ghrelin levels. All statistical analysis were 
performed with SPSS 11.5  software, p〈0.05 was considered statistically significant. 
 
 
5. Results 
 
  
    5.1     Anthropometric data and hormonal parameters 
 
No signficant correlation was observed between anthropometric parameters (sex, mode 
of birth, gestational age, birth weight) and maternal and fetal hormonal parameters 
(acylated ghrelin, total ghrelin, cortisol, insulin, leptin). There was a significant 
correlation (Table 1) between placental weight and acylated ghrelin levels of neonates 
(r=0.396, p=0.045) and between placental weight and GH levels of neonates (r=0.483, 
p=0.008). 
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Table 1  Spearman’s correlation coefficient between the various studied hormones, 
glucose and anthropometric data in the fetus  ∗ p〈0.05 
 
 Acylated 
ghrelin 
Total 
ghrelin 
Cortisol Insulin Glucose Leptin GH 
Gestational 
age 
0.266 
p=0.190 
-0.221 
p=0.268 
0.480 
p=0.010* 
0.131 
p=0.498 
0.005 
p=0.980 
0.362 
P=0.075 
-0.195 
p=0.310 
Birth 
weight 
0.038 
p= 0.855 
-0.104 
p=0.604 
0.422 
p= 0.025 
0.247 
p=0.196 
0.008 
p=0.968 
0.334 
p=0.103 
-0.304 
p=0.109 
Placental 
weight 
0.396 
p=0.045* 
0.158 
p=0.431 
0.149 
p= 0.448 
0.171 
p=0.375 
-0.161 
p=0.422 
0.085 
p=0.685 
0.483 
p=0.008* 
Acyl-
ghrelin 
1.00 0.050 
p=0.812 
0.547 
p=0.005* 
0.004 
p=0.984 
0.213 
p=0.306 
0.076 
p=0.737 
-0.009 
p = 0.966 
Total 
Ghrelin 
 1.00 0.260 
p = 0.200 
0.039 
p=0.846 
0.154 
p=0.453 
-0.243 
p=0.264 
-0.234 
p = 0.239 
Cortisol   1.00 -0.040 
p=0.841 
0.254 
p=0.201 
-0.029 
p=0.890 
0.035 
p = 0.861 
Insulin    1.00 0.509 
p=0.007* 
0.184 
p=0.379 
-0.367 
p=0.050* 
Glucose     1.00 -0.083 
p=0.700 
-0.031 
p=0.878 
Leptin      1.00 -0.267 
p=0.197 
GH 
 
      1.00 
 
                     
 
       5.2   Maternal and fetal hormonal parameters 
 
The acylated and total ghrelin were detectable in all samples. Table 2 shows the 
maternal and fetal concentrations of ghrelin, cortisol, insulin, glucose, leptin and GH. 
 
 
                Table 2 Maternal and fetal concentrations of ghrelin, cortisol,  
                Insulin, glucose, leptin and GH 
                ----------------------------------------------------------------------------- 
                                                        Maternal (n=23)              Fetal (n=26) 
                  ---------------------------------------------------------------------------- 
                  Acyl-ghrelin(pg/ml)           73.1±33.1                   36.5±14.6* 
                  Total ghrelin(pg/ml) 295.9±41.3                   611.9±183.2*                                                                  
                  Cortisol(nmol/l)               1082.6±528.8                174.1±74.6* 
                  Insulin(mU/l)                     44.2±43.5                     15.4±15.6* 
                  Glucose(mmol/l)                  7.4±2.3                        5.6±1.2* 
                  Leptin(ng/ml)                     28.9±13.3                    0.86±0.76* 
                  GH(µg/l)                              2.6±3.8                      60.2±33.2* 
                  ----------------------------------------------------------------------------                                 
                  All data are presented as means±S.D.; n=number of cases, ∗p〈0.01 
                  versus mother with Mann-Whitney test 
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The mean level of acylated ghrelin concentration was higher in the maternal vein than in 
the cord vein (73.1 ± 33.1 vs 36.5 ± 14.6 pg/ml, p〈0.01). Overall, there was a significant 
correlation (Fig.3) between the fetal and maternal acylated ghrelin levels (r=0.771, 
p〈0.001). The total ghrelin concentration was higher in the neonates, than in the mothers 
(611.9 ± 183.2 vs 295.9 ± 41.3 pg/ml, p〈0.01), but no significant correlation between the 
fetal and maternal total ghrelin levels was found. 
 
Figure 3   Correlation  between  paired  maternal  and fetal plasma acylated ghrelin and  
cortisol concentrations   
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        5.3    Correlations among the various hormonal parameters 
 
The bivariate correlations of cord vein hormones (Table1) show a significant 
correlations between the cord vein acylated ghrelin and cord vein cortisol levels (r= 
0.547, p〈0.005). Total and acylated ghrelin levels in the cord vein were unrelated to 
other studied  hormones in the fetuses. 
The bivariate correlations of mother vein hormones (Table 3) show a negative 
correlation between the total ghrelin and glucose (r = - 0.577, p 〈 0.003) and between the 
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total ghrelin and insulin (r = -510, p 〈 0.008 ). Acylated ghrelin levels in the mothers 
were unrelated to the studied hormones.  
 
Table 3  Spearman’s correlation coefficient between the various studied hormones  and glucose 
in the mothers  ∗p〈0.05 
 
  Acylated 
ghrelin 
Total 
ghrelin 
Cortisol Insulin Glucose Leptin GH 
 
Acylated 
Ghrelin 
1.00 -0.290 
p=0.169 
-0.019 
p=0.930 
0.165 
p=0.452 
0.101 
p=0.656 
-0.175 
p=0.425 
-0.066 
p=0.759 
Total 
Ghrelin 
 1.00 0.096 
p=0.641 
-0.510 
p=0.008* 
-0.577 
p=0.003* 
0.215 
p=0.291 
0.131 
p=0.516 
Cortisol   1.00 0.035 
p=0.865 
0.229 
p=0.271 
-0.396 
p=0.041* 
0.027 
p=0.893 
Insulin    1.00 0.772 
p=0.0001* 
0.047 
p=0.820 
0.087 
p=0.665 
Glucose     1.00 -0.020 
p=0.924 
0.005 
p=0.981 
Leptin      1.00 -0.121 
p=0.547 
GH 
 
      1.00 
 
 
The Figure 3 shows the significant univariate correlations between mothers and their 
fetuses in the case of acylated ghrelin (r=0.771, p〈0.001) and the cortisol levels (r=0.606, 
p〈0.01). The correlation between maternal and fetal cortisol concentrations remained 
significant after correction for the number of hours since the last injection of 
betamethasone. 
 
 
5.4  Multivariate regression analysis 
 
The Multiple Regression Model was created by use stepwise method, starting from all 
variables with a significant univariate correlation with any of the indices. Before the 
stepwise regression we examined with Spearman’s correlation the relationship the fetal 
and maternal hormones and glucose (Table 4).  
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Table 4 Spearman’s correlation coefficient between mothers and fetuses  ∗ p 〈 0.05 
 
 
       
The summary of the stepwise multivariate regression analysis for fetal acylated ghrelin 
and  maternal total ghrelin as dependent variables and the placental weight, maternal 
acylated ghrelin, fetal cortisol and the maternal glucose, maternal insulin, fetal glucose 
as independent variables is presented in Table 5. 
 
Table 5  Multiple  regression  model  with  indices  of   fetal acylated and maternal           
 total ghrelin as dependent variables  β denotes the regression slope  *p〈0.05            
------------------------------------------------------------------------------------------------------ 
                                             Fetal acylated ghrelin              Maternal total ghrelin 
------------------------------------------------------------------------------------------------------ 
                                                   R2=0.639                                     R2=0.184 
     Maternal acylated ghrelin     β=0.733, p=0.0001     
     Maternal cortisol                   β=0.286, p=0.038 
     Maternal glucose                                                                      β=-0.467, p=0.019 
 ----------------------------------------------------------------------------------------------------- 
 
The adjusted R2 was 0.639  in the case of fetal acylated ghrelin with maternal acylated 
ghrelin (β=0.733, p=0.0001) and with the fetal cortisol (β=0.286, p=0.038), the variables 
have statistically significant correlations with the fetal acylated ghrelin. The adjusted R2 
was 0.184  in the case of maternal total ghrelin with maternal glucose (β=-0.467, p = 
0.019), the only variable with statistically significant correlation with maternal total 
ghrelin. There was no independent predictor when the maternal acyl ghrelin or fetal total 
ghrelin were used as dependent variables. 
 Maternal    
Fetal 
Acyl- 
ghrelin 
Total 
ghrelin 
Cortisol Insulin Glucose Leptin GH 
Acyl- 
ghrelin 
0.771 
p=0.001* 
-0.176 
p=0.390 
0.368 
p=0.070 
0.156 
p=0.457 
0.296 
p=0.151 
0.191 
p=0.360 
0.084 
p=0.683 
Total 
ghrelin 
-0.342 
p=0.101 
0.187 
p=0.350 
0.363 
p=0.069 
0.155 
p=0.450 
0.132 
p=0.520 
-0.143 
p=0.486 
0.036 
p=0.859 
Cortisol 0.061 
p=0.770 
-0.186 
p=0.342 
0.606 
p=0.01* 
-0.095 
p=0.637 
0.369 
p=0.053 
-0.230 
p=0.238 
-0.082 
p=0.679 
Insulin 0.144 
p=0.482 
-0.296 
p=0.120 
0.020 
p=0.921 
0.279 
p=0.151 
0.390 
p=0.040* 
0.140 
p=0.476 
-0.178 
p=0.356 
Glucose 0.023 
p=0.915 
-0.431 
p=0.025* 
-0.029 
p=0.887 
0.141 
p=0.493 
0.618 
p=0.001* 
0.306 
p=0.121 
0.186 
p=0.353 
Leptin 0.119 
p=0.599 
0.068 
p=0.748 
-0.233 
p=0.263 
-0.244 
p=0.251 
-0.180 
p=0.390 
0.325 
p=0.134 
-0.178 
p=0.356 
GH 0.067 
p=0.743 
0.078 
p=0.687 
-0.159 
p=0.420 
-0.143 
p=0.469 
-0.132 
p=0.504 
0.070 
p=0.722 
0.283 
p=0.137 
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                                          6. Summary of the results and conclusions 
 
 
 
Ghrelin was discovered as a hormone related to GH secretion. With  advancing 
gestational age, the placental production of GH is elevated. We  found correlation 
between placental weight and GH levels of neonates. Data available are not consistent: 
association among circulating total ghrelin and the GH have been reported by some but 
not by others. It is generally assumed that the GH-releasing activity of ghrelin is 
dependent on its acylation in serine3. We have not found correlatins between acylated or 
total ghrelin and GH concentration, which support the hypothesis that ghrelin is not 
contributing to the high GH concentrations observed during gestation. 
However, there was a significant correlation between acylated ghrelin levels of neonates 
and the placental weight. It is contradictory with Yokota et al, however  they examined  
full-term newborns who were not only of the group of adequate-for-gestational age. It is 
known, that the ghrelin levels of small-for-gestational age are greater than those of 
appropriate-for-gestational age infants. Further investigation is need to show the possible 
relationship between the placenta and the acylation process of ghrelin. 
Similarly to others, we didn’n found correlation between maternal and newborn total 
ghrelin, but we found significant correlation between the fetal and maternal acylated 
ghrelin levels. It is possible that acylated ghrelin could cross the placenta in human as 
suggested by Nakahara in rat. The hypothesis that the placenta may play a role in the 
acylation process is supported in part by the relationship between fetal acylated ghrelin 
concentration and the placental weight. 
In addition to its GH-relasing properties, ghrelin appears to be related to regulation of 
apetite and glucose metabolism. It is known that ghrelin secretion is increased by fasting 
and decreased by food intake, glucose and insulin in adults, and there is a negative 
association between ghrelin and insulin secretion. We also found a negative correlation 
between total ghrelin and glucose, as well as between total ghrelin and insulin 
concentrations in the mother’s blood only.  Farquhar et al. found a similar relationship 
between cord plasma ghrelin and glucose concentrations. However, in our experiment, 
the mothers with known gestational diabetes were excluded, in contrast to referred 
authors, where the prevalence of maternal diabetes was considerable. 
Leptin is detectable in cord blood from early in the second trimester and circulating 
levels of cord blood leptin are positively correlated with birth weight and cord plasma 
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insulin levels in full-term newborns. These results seem to be inconsistent with our 
findings, because we have not found any correlation with cord blood leptin. The 
discrepancy may be explained by gestational age, because more than 98% of leptin 
secreted by placenta goes to the maternal side, presumably the fetal leptin is being 
produced by fetal adipose or other tissues. The number of studies have shown that there 
is a sexual dimorphism in plasma leptin concentrations during the later period of life. 
During the examination period, the concentration of leptin in the cord blood was very 
low, and we did not see significant differences between male and female infants. 
The multiple regression model shows a relationship between the fetal cortisol and fetal 
acylated ghrelin concentration. We have measured the maternal and fetal plasma cortisol 
levels in parallel and the results were consistent with others: the maternal plasma cortisol 
levels were ten times higher than fetal plasma cortisol and there was a significant linear 
correlation between them. The limitation of our study is the fact that all mothers 
received betamethasone. The prenatal betamethasone administration to mothers  has 
been shown to result in similar betamethasone  concentrations in maternal and fetal 
serum. It is known that prenatal maternal betamethasone therapy suppresses the cortisol 
levels  within 1 week of betamethasone treatment, as long as the synthetic glucocorticoid 
remains in circulation. It is known that synthetic glucocorticoids have genomic potencies 
several times that of cortisol, this support the hypothesis that there is no close 
relationship between the efficiency of non-genomic and classical genomic responses of 
different glucocorticoids. Our results show a positive correlation between fetal cortisol 
and acylated ghrelin, this suggests the possibility that the cortisol may be involved in the 
acylation process of ghrelin through a non-genomic action. 
 
Several new findings  are reported in the present study. These data provide first evidence 
that in premature newborns umbilical cord acylated ghrelin concentrations are lower that 
in maternal blood, and the fetal acylated ghrelin correlate with maternal acylated ghrelin 
and the fetal cortisol. The physiological role of ghrelin during pregnancy remains to be 
clarified, buti t may be  related to the degree of acylation. The correlation of the fetal 
acylated ghrelin with the placental weight supports the hypothesis that the placenta may 
play a role in the acylation process and may be partly affected by cortisol. 
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